Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts

Maturitas

Volumn 65, Issue 3, 2010, Pages 258-261

  Lipovac, Markus ^a   Chedraui, Peter ^b   Gruenhut, Christine ^c   Gocan, Ana ^c   Stammler, Maria ^d   Imhof, Martin ^a  

^a Division of Obstetrics   (Austria)

^b Instituto Para la Salud de la Mujer   (Ecuador)

^c Study Center Med XIX   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anxiety; Depressive mood; Isoflavones; Postmenopause; Red clover

Indexed keywords

ISOFLAVONE; PLACEBO; RED CLOVER EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ZUNG SELF RATING DEPRESSION SCALE;

AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; TRIFOLIUM;

TRIFOLIUM PRATENSE;

EID: 76349088258     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.10.014     Document Type: Article

References (52)

1. Wells K.B., Stewart A., Hays R.D., et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262 (1989) 914-919
2. Kouzis A.C., and Eaton W.W. Emotional disability days: prevalence and predictors. Am J Public Health 84 (1994) 1304-1307
3. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., and Nelson C.B. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 29 (1993) 85-96
4. Barry K.L., Fleming M.F., Manwell L.B., Copeland L.A., and Appel S. Prevalence of and factors associated with current and lifetime depression in older adult primary care patients. Fam Med 30 (1998) 366-371
5. Amick III B.C., Kawachi I., Coakley E.H., Lerner D., Levine S., and Coldtiz G.A. Relationship of job strain and iso-strain to health status in a cohort of women in the United States. Scand J Work Environ Health 24 (1998) 54-61
6. Schmidt P.J., Murphy J.H., Haq N., Rubinow D.R., and Danaceau M.A. Stressful life events, personal losses, and perimenopause-related depression. Arch Women Ment Health 7 (2004) 19-26
7. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
8. Woods N.F., Mariella A., and Mitchell E.S. Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Climacteric 9 (2006) 195-203
9. Juang K.D., Wang S.J., Lu S.R., Lee S.J., and Fuh J.L. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 52 (2005) 119-126
10. Woods N.F., Mariella A., and Mitchell E.S. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 81 (2002) 623-632
11. Woods N.F., Smith-DiJulio K., Percival D.B., Tao E.Y., Mariella A., and Mitchell E.S. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause 15 (2008) 223-232
12. Freeman E.W., Sammel M.D., Lin H., Gracia C.R., Kapoor S., and Ferdousi T. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause 12 (2005) 258-266
13. Sierra B., Hidalgo L.A., and Chedraui P.A. Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale. Maturitas 51 (2005) 236-245
14. Chedraui P., Aguirre W., Hidalgo L., and Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. Maturitas 57 (2007) 271-278
15. Monterrosa A., Blumel J.E., and Chedraui P. Increased menopausal symptoms among Afro-Colombian women as assessed with the Menopause Rating Scale. Maturitas 59 (2008) 182-190
16. Chedraui P., Hidalgo L., Chavez D., Morocho N., Alvarado M., and Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 275 (2007) 161-168
17. Bhavnani B.R., and Strickler R.C. Menopausal hormone therapy. J Obstet Gynaecol Can 27 (2005) 137-162
18. Castelo-Branco C., and Rostro F. Management of menopause. Minerva Ginecol 58 (2006) 137-152
19. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
20. Blumel J.E., Castelo-Branco C., Chedraui P.A., et al. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 11 (2004) 57-61
21. Ettinger B., Grady D., Tosteson A.N., Pressman A., and Macer J.L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 102 (2003) 1225-1232
22. Lazar Jr. F., Costa-Paiva L., Morais S.S., Pedro A.O., and Pinto-Neto A.M. The attitude of gynecologists in Sao Paulo, Brazil 3 years after the Women's Health Initiative study. Maturitas 56 (2007) 129-141
23. Nassar A.H., Abd Essamad H.M., Awwad J.T., Khoury N.G., and Usta I.M. Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era. Maturitas 52 (2005) 18-25
24. Miksicek R.J. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 44 (1993) 37-43
25. Miksicek R.J. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 49 (1994) 153-160
26. Dornstauder E., Jisa E., Unterrieder I., Krenn L., Kubelka W., and Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 78 (2001) 67-75
27. Simoncini T., Fornari L., Mannella P., et al. Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause 12 (2005) 69-77
28. Simoncini T., Garibaldi S., Fu X.D., et al. Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause 15 (2008) 542-550
29. Mueller M., and Jungbauer A. Red clover extract: a putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome. Menopause 15 (2008) 1120-1131
30. Adaikan PG, Srilatha B, Wheat AJ. Efficacy of red clover isoflavones in the menopausal rabbit model. Fertil Steril 2008; In press.
31. Imhof M., Gocan A., Reithmayr F., et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 55 (2006) 76-81
32. Chedraui P., Hidalgo L., San Miguel G., Morocho N., and Ross S. Red clover extract (MF11RCE) supplementation and postmenopausal vaginal and sexual health. Int J Gynaecol Obstet 95 (2006) 296-297
33. Hidalgo L.A., Chedraui P.A., Morocho N., Ross S., and San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 21 (2005) 257-264
34. Chedraui P., San Miguel G., Hidalgo L., Morocho N., and Ross S. Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index. Gynecol Endocrinol 24 (2008) 620-624
35. Coon J.T., Pittler M.H., and Ernst E. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine 14 (2007) 153-159
36. Zigmond A.S., and Snaith P.R. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67 (1983) 361-370
37. Zung W.W.K. A self-rating depression scale. Arch Gen Psychiatry 12 (1965) 63-70
38. Craig M.C., and Murphy D.G. Estrogen: effects on normal brain function and neuropsychiatric disorders. Climacteric 10 (2007) 97-104
39. Joffe H., Hall J.E., Soares C.N., et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 9 (2002) 392-398
40. Chedraui P., Morales B., and Hidalgo L. Depression and related risk factors among climacteric women. Climacteric 11 (2008) 125
41. Szoeke C.E., Cicuttini F.M., Guthrie J.R., and Dennerstein L. The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 11 (2008) 55-62
42. Chedraui P., San Miguel G., and Avila C. Quality of life impairment during the female menopausal transition ir related to personal and partner factors. Gynecol Endocrinol; Gynecol Endocrinol 25 (2009) 130-135
43. Chedraui P., Blümel J.E., Baron G., et al. Impaired quality of life among middle aged women: a multicentre Latin American study. Maturitas 61 (2008) 323-329
44. Bodo C., and Rissman E.F. New roles for estrogen receptor beta in behavior and neuroendocrinology. Front Neuroendocrinol 27 (2006) 217-232
45. Albert A., Altabre C., Baró F., et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine 9 (2002) 85-92
46. Chen H.Q., Wang X.J., Jin Z.Y., Xu X.M., Zhao J.W., and Xie Z.J. Protective effect of isoflavones from Trifolium pratense on dopaminergic neurons. Neurosci Res 62 (2008) 123-130
47. Occhiuto F., Zangla G., Samperi S., et al. The phytoestrogenic isoflavones from Trifolium pratense L. (Red clover) protects human cortical neurons from glutamate toxicity. Phytomedicine 15 (2008) 676-682
48. Occhiuto F., Palumbo D.R., Samperi S., Zangla G., Pino A., De Pasquale R.D., et al. The isoflavones mixture from Trifolium pratense L. protects HCN 1-A neurons from oxidative stress. Phytother Res 23 (2008) 192-196
49. Bu L., and Lephart E.D. Soy isoflavones modulate the expression of BAD and neuron-specific beta III tubulin in male rat brain. Neurosci Lett 385 (2005) 153-157
50. Lephart E.D., Setchell K.D., Handa R.J., and Lund T.D. Behavioral effects of endocrine-disrupting substances: phytoestrogens. ILAR J 45 (2004) 443-454
51. Lephart E.D., West T.W., Weber K.S., et al. Neurobehavioral effects of dietary soy phytoestrogens. Neurotoxicol Teratol 24 (2002) 5-16
52. Lund T.D., and Lephart E.D. Dietary soy phytoestrogens produce anxiolytic effects in the elevated plus-maze. Brain Res 913 (2001) 180-184